Effects of exogenous porcine somatotropin on the carcass composition, hormonal and metabolic profiles, lipogenic capacity, and binding of insulin to erythrocyte receptors of fast- versus slow-growing swine.
Twenty barrows were designated as fast-growing (FG) and their littermates designated as slow-growing (SG) based on birth, weaning, and 56-d weight. Half of each group received 70 micrograms of porcine somatotropin (pST)/kg BW daily beginning at 40 kg BW. At 60 and 105 kg BW, blood was collected every .5 h for 12 h beginning 1 h before pST injection, fat biopsies were taken for in vitro lipogenic activity, and insulin erythrocytes were isolated for receptor binding. Swine treated with pST had elevated ADG (.95 vs .88 kg/d; P < .1) and reduced days to slaughter (61 vs 67; P < .1). The pST-treated pigs had less average backfat (2.73 vs 3.96 cm; P < .01), larger longissimus muscle areas (32.3 vs 28.2 cm2; P < .05), and a higher percentage of muscle (56.3 vs 50.3%; P < .01) than control pigs. Exogenous pST increased protein (17.4 vs 13.2%; P < .05) and decreased fat (22.9 vs 37.1%; P < .05). The FG pigs had higher ADG (.98 vs .86 kg/d; P < .01) and required fewer days to slaughter (57 vs 71; P < .01) than SG pigs. Administration of pST increased (P < .01) average pST levels (1.7 vs 14.0 ng/mL) in FG and SG pigs at 60 kg BW. At 105 kg BW, pST was higher (P < .01) in pST-FG than in pST-SG swine (46.0 vs 19.3 ng/mL) but was not different between FG and SG control swine (1.9 vs 1.8 ng/mL). Administration of pST increased concentrations of IGF-I (510.0 vs 160.0 ng/mL) and nonesterified fatty acids (182 vs 109 muEq/L, P < .01) in FG and SG swine. Over sample periods and growth rates, pST reduced (P < .05) CO2 production and lipid synthesis (.345 and 1.85 vs .575 and 2.71 mumol of glucose incorporated.g-1.2 h-1). At 60 kg BW, FG swine had less (P < .01) CO2 production and lipid synthesis (.299 and 1.83 vs .921 and 3.61 mumol.g-1.2 h-1) than did SG swine. Exogenous pST increased (P < .05) binding to insulin erythrocyte receptors (7.25 vs 6.34%).
Mikel
W B
WB
Department of Animal and Dairy Sciences, Auburn University, AL 36849.
Althen
T G
TG
Rogers
R W
RW
Moore
A B
AB
Miller
H W
HW
Miller
L F
LF
D000273:Adipose Tissue / Q000187:drug effects / Q000254:growth & development; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001806:Blood Urea Nitrogen; D001823:Body Composition / Q000187:drug effects*; D004912:Erythrocytes / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D013006:Growth Hormone / Q000097:blood / Q000494:pharmacology*; D006728:Hormones / Q000097:blood*; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008055:Lipids / Q000096:biosynthesis*; D008297:Male; D008460:Meat / Q000592:standards; D024510:Muscle Development; D009132:Muscles / Q000187:drug effects; D011897:Random Allocation; D011972:Receptor, Insulin / Q000378:metabolism; D013552:Swine / Q000254:growth & development / Q000378:metabolism*; D015430:Weight Gain / Q000187:drug effects
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D006728:Hormones; D007328:Insulin; D008055:Lipids; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D011972:Receptor, Insulin